Vaxcyte (PCVX) Long-Term Investments (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Long-Term Investments data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 21.5% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 21.5% decrease from a year earlier, with the FY2025 full-year figure at $881.7 million, down 36.46% from the prior year.
• Long-Term Investments for Q1 2026 stood at $1.0 billion, up from $881.7 million in the prior quarter.
• Over the last five years, Long-Term Investments for PCVX reached as high as $1.4 billion in Q4 2024 and fell as low as $4.0 million in Q3 2022.
• Historically, Long-Term Investments has averaged $544.1 million across 5 years, with a median of $399.2 million in 2024.
• Across the five-year window, Long-Term Investments sank 89.99% in 2022 and jumped 4138.47% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $26.5 million in 2022, then jumped by 512.73% to $162.7 million in 2023, then soared by 752.93% to $1.4 billion in 2024, then sank by 36.46% to $881.7 million in 2025, then grew by 13.88% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $1.0 billion in Q1 2026, $881.7 million in Q4 2025, and $959.3 million in Q3 2025.